Purchase of Measles Rubella (MR) Vaccine Concentrate on F.O.R, NIH Islamabad

The National Institutes of Health (NIH) Islamabad is procuring Measles Rubella (MR) Vaccine Concentrate for the fiscal year 2026-27. This procurement is critical for the ongoing immunization programs and public health initiatives in Islamabad. The items being procured: - Measles Rubella (MR) Vaccine Concentrate This procurement is managed by the National Institutes of Health (NIH) located in Islamabad Capital Territory. The vaccine concentrate will be supplied on F.O.R basis to NIH Islamabad. The procurement follows the Single Stage-Two Envelope procedure using the Least Cost Based Selection (LCBS) technique in accordance with Public Procurement Rules, 2004. Bidders must submit a bid security in the form of Pay Order, Call Deposit, or Demand Draft as specified in the bidding documents. Eligibility criteria include registration on EPADS v2.0, compliance with FBR/ATL registration, and adherence to all regulatory guidelines. The bidding documents with detailed terms, conditions, and specifications are available on the e-Pak Acquisition and Disposal System (EPADS) portal. Bidders must be registered on EPADS v2.0 to participate. The key submission deadline is Tuesday, July 28, 2026, by 11:00 AM, with bid opening scheduled for 11:30 AM the same day via EPADS v2.0. Manual submissions will not be entertained. Interested bidders should ensure timely registration on EPADS and carefully follow the instructions to avoid disqualification. A practical tip for bidders is to complete their EPADS registration well in advance and thoroughly review the bid security requirements to ensure compliance. This will help avoid last-minute issues and ensure a smooth bidding process.